This year will be “transformative” for Intezyne, a Tampa biopharmaceutical firm, according to Russell McAllister, the new president and CEO.
The company, which is developing treatments for cancer, is actively evaluating a variety of strategic options, including a Series B funding round in advance of a potential initial public offering, McAllister said in a news release announcing his promotion.
